Kirchgraber Paul R 4
4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 23, 2023
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Sale
Common Stock
2023-02-21$250.58/sh−8,000$2,004,675→ 9,069 total - Exercise/Conversion
Non-qualified Stock Options
2023-02-21−3,000→ 4,300 totalExercise: $182.51From: 2021-02-04Exp: 2030-02-03→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2023-02-21$182.51/sh+3,000$547,530→ 17,069 total
Footnotes (3)
- [F1]The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- [F2]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- [F3]The option vested in three equal annual installments beginning on the date reflected in this column.